Shares of Dexcom tumbled more than 35% in extended trading Thursday after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance.
The company reported net income of $143.5 million, up from the $115.9 million it reported during the same period last year.
Dexcom updated its full fiscal year guidance to reflect expected revenue between $4 billion and $4.05, which is down from the $4.20 billion to $4.35 billion it forecast last quarter.
"While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," Dexcom CEO Kevin Sayer said in the release.
In March, the company announced its new over-the-counter CGM called Stelo had been cleared for use by the U.S. Food and Drug Administration.
Persons:
LSEG, Dexcom, Kevin Sayer, Stelo
Organizations:
LSEG Revenue, U.S . Food, Drug Administration